Essentialis Taps Insiders For Series B, Shops Triglyceride Drug By Brian Gormley 10/11/2010
Essentialis Inc., which has seen good results from mid-stage trials of a drug aimed at patients with very high triglyceride levels, has raised new Series B funding as it shops the compound to potential corporate partners, according to one of its executives. Insiders Forward Ventures, Palo Alto Investors, Technology Partners and Vivo Ventures provided an undisclosed amount of capital over the summer, said Chief Commercial Officer Aaron D. Berg. He declined to discuss Essentialis' financing history, but VentureWire previously reported that the company closed a $14 million Series A round in 2007.
No need to go on further, but for those individuals who don't know, MMR did a reverse merger into FVRL (FVRL), to go public and trust me, there is still plenty of untapped value in the biotech asset value!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.